EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Intensive Blood Pressure Lowering and Renal Function in Ischemic Stroke Patients: Secondary Analysis of the ENCHANTED Trial

Chen Chen, Xinwen Ren, Yang Zhao, Menglu Ouyang, Qiang Li Mbiostat, Xia Wang, Yunke Li, Shoujiang You, Yanan Wang, Thompson G Robinson, Richard Lindley, Hisatomi Arima und 6 weitere

Cerebrovascular Diseases · 2024

DOI: 10.1159/000536275 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cerebrovascular Diseases, 2024. Verfasst von Chen Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, 15921119641@163.com. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Antihypertensive Agents, Kidney, Ischemic Stroke. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Renal failure is a major safety concern of intensive systolic blood pressure (SBP) lowering. We aimed to determine the effect of this treatment on early change in renal function in participants of the international Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).

Methods

Post hoc analysis of the ENCHANTED BP-arm in which thrombolyzed patients with acute ischemic stroke (AIS) were randomized to intensive (target 130–140 mm Hg within 1 h) or guideline-recommended (target <180 mm Hg) management within 6 h of symptom onset. Primary outcome is the early change in renal function, defined by a difference in estimated glomerular filtration rate (∆eGFR = 24 h – baseline eGFR), analyzed using linear regression with adjustment for clinical variables. Key SBP parameters were attained (mean), variability (standard deviation), and magnitude of reduction within 24 h.

Results

Of 2,151 participants (mean age 66.9 years; 38% female) included with the available baseline eGFR, there were significant differences in attained 144.3 ± 10.2 versus 149.8 ± 12.0 [Δ5.5 mm Hg]; p < 0.0001), variation (15.1 ± 5.4 vs. 14.0 ± 5.6 mm Hg; p < 0.0001), and magnitude of reduction (44.6 ± 16.2 vs. 38.7 ± 17.6 mm Hg; p < 0.0001) in SBP within 24 h. 1,718 (79.9%) participants with complete follow-up eGFR were included in the primary analysis, and there was no significant difference in ∆eGFR (adjusted mean difference −1.10, 95% confidence interval [CI] −3.14 to −0.94; p = 0.29) between the intensive and guideline groups, respectively. The neutral effect on ∆eGFR was consistent in patients with different baseline eGFR stages and in sensitivity analysis after multiple imputations for missing follow-up eGFR. SBP variability was significantly associated with decreasing ∆eGFR (per 5 mm Hg increase by category: adjusted mean difference −1.35, 95% CI: −2.43 to −0.28; p for trend = 0.01).

Conclusion

Intensive SBP lowering with a target of 130–140 mm Hg had no impact on early renal function in thrombolyzed AIS patients. Wide SBP variability was associated with a larger decline in eGFR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateAntihypertensive AgentsKidneyIschemic StrokeBlood PressureHypertensionHumansFemaleMaleAgedMiddle AgedTreatment OutcomeTime FactorsRisk FactorsThrombolytic TherapyFibrinolytic AgentsRenal Insufficiency

Stichwörter der Autor:innen

Acute ischemic strokeBlood pressureEstimated glomerular filtration rateRenal functionSafetyThrombolysis

Substanzen

Antihypertensive AgentsFibrinolytic Agents

Autor:innen und Institutionen

  • Neurology Department, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, 15921119641@163.com.
  • The George Institute for Global Health China, Beijing, China, 15921119641@163.com.
  • The George Institute for Global Health, Faculty of Medicine, University of New South Wales, NSW, Sydney, Australia, 15921119641@163.com.
  • The George Institute for Global Health China, Beijing, China.
  • The George Institute for Global Health, Faculty of Medicine, University of New South Wales, NSW, Sydney, Australia.
  • Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of SooChow University, Suzhou, China.

Zitieren

APA

Chen, C., Ren, X., Zhao, Y., Ouyang, M., Li Mbiostat, Q., Wang, X., Li, Y., You, S., Wang, Y., Robinson, T. G., Lindley, R., Arima, H., Chalmers, J., Li, G., Chen, X., Anderson, C. S., Song, L., & ENCHANTED Investigators (2024). Intensive Blood Pressure Lowering and Renal Function in Ischemic Stroke Patients: Secondary Analysis of the ENCHANTED Trial. Cerebrovascular Diseases. https://doi.org/10.1159/000536275

Vancouver

Chen C, Ren X, Zhao Y, Ouyang M, Li Mbiostat Q, Wang X, et al. Intensive Blood Pressure Lowering and Renal Function in Ischemic Stroke Patients: Secondary Analysis of the ENCHANTED Trial. Cerebrovascular Diseases. 2024. doi:10.1159/000536275

BibTeX
@article{Chen2024,
  author = {Chen, Chen and Ren, Xinwen and Zhao, Yang and Ouyang, Menglu and Li Mbiostat, Qiang and Wang, Xia and Li, Yunke and You, Shoujiang and Wang, Yanan and Robinson, Thompson G and Lindley, Richard and Arima, Hisatomi and Chalmers, John and Li, Gang and Chen, Xiaoying and Anderson, Craig S and Song, Lili and ENCHANTED Investigators, ENCHANTED Investigators},
  title = {Intensive Blood Pressure Lowering and Renal Function in Ischemic Stroke Patients: Secondary Analysis of the ENCHANTED Trial},
  journal = {Cerebrovascular Diseases},
  year = {2024},
  doi = {10.1159/000536275}
}
Kostenlos starten →